What the April 18, 2026 executive order on psychedelics does — Priority Vouchers, $50M ARPA-H funding, Right to Try, and what it does not do.
On April 18, 2026, President Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness. The order is the most significant federal policy shift on psychedelics since the Controlled Substances Act of 1970.
The Trump psychedelics executive order tells federal agencies to move faster on psychedelic drug approvals. It also tells them to open new access pathways for patients with serious mental illness. But the order does not legalize any psychedelic drug.
In plain terms, the order shortens the time the FDA needs to review psychedelic drugs. It also funds state research programs. And it asks the DEA to be ready to reschedule drugs as soon as the FDA approves them.
Veterans groups have pushed for years to expand access to ibogaine and MDMA. The order names ibogaine directly. It also gives a clear federal signal that the White House supports the psychedelic medicine pipeline.
Industry watchers expect the order to speed up FDA decisions on psilocybin for depression. It may also shorten the path for ibogaine for addiction, if Phase 3 trials clear key safety hurdles.
The executive order has four main parts. Each one directs a specific federal agency to take action. The table below summarizes what each provision does and which agency is responsible.
| Provision | Agency | What it does |
|---|---|---|
| National Priority Vouchers | FDA | Directs the FDA Commissioner to give Priority Vouchers to psychedelic drugs with Breakthrough Therapy designation. Voucher review targets 1–2 months instead of the usual 6–10 months. |
| Right to Try pathway | FDA + DEA | Directs the FDA and DEA to build a pathway letting eligible patients access investigational psychedelics under review, including ibogaine. Patients must meet safety criteria. |
| $50M ARPA-H funding | HHS / ARPA-H | Allocates $50 million through the Advanced Research Projects Agency for Health (ARPA-H) to match state government investments in psychedelic research. |
| Rescheduling reviews | Attorney General / DEA | Directs the Attorney General to start rescheduling reviews as soon as a psychedelic drug completes Phase 3 trials. This positions the DEA to act faster after FDA approval. |
On April 24, 2026, six days after the order was signed, the FDA awarded the first three National Priority Vouchers for psychedelic drugs. Two went to psilocybin programs and one went to methylone.
MDMA was notably absent from the first round. The FDA rejected the Lykos MDMA-for-PTSD application in August 2024. A new Phase 3 trial is required before any voucher would apply.
Headlines have called the order historic. But the legal reality is narrower than many readers expect. Here is what the Trump psychedelics executive order does not change.
Harvard Law's Petrie-Flom Center notes that presidents cannot legally compel drug rescheduling. The DEA already has a statutory duty to act within 90 days after FDA approval. So the rescheduling provision is more of a signal than a new legal power.
Psilocybin is the biggest winner so far. Two of the three first Priority Vouchers went to psilocybin programs. Federal approval for treatment-resistant depression now looks possible by 2027 or 2028.
Read our full psilocybin therapy guide for trial details and state-level access in Oregon and Colorado.
MDMA was not in the first voucher round. After the FDA rejected Lykos in August 2024, the field needs a fresh Phase 3 trial. Resilient Pharmaceuticals (formerly Lykos) plans a new trial, but timelines slip beyond 2027.
Our MDMA-assisted therapy guide tracks the rebuilt trial plan. The global MDMA legal status guide covers Australia, the only country with legal MDMA therapy today.
Ibogaine got the most direct shout-out in the order. Veterans groups have lobbied hard for ibogaine access to treat opioid addiction and combat-related trauma. Texas allocated $50 million for ibogaine research in 2025.
But ibogaine carries real cardiac risks. Harvard law experts have flagged that the order's Right to Try language for ibogaine may be hard to use, since ibogaine has limited Phase I US safety data. See our ibogaine guide for the cardiac safety profile.
DMT is not specifically named in the executive order. The four DEA religious exemptions for ayahuasca are unaffected. Small Pharma (now Helus Pharma) continues SPL026 DMT trials for depression.
Our DMT guide and DMT legal status guide cover federal status, Colorado decrim, and the four exempted churches.
Reactions to the order have been mixed. Industry leaders welcomed the federal signal. Legal scholars raised practical concerns about what the order can and cannot do.
Veterans groups and ibogaine advocates have called the order a turning point. The American Legion endorsed psychedelic research in a 2023 resolution. The order delivers on years of advocacy from those organizations.
Industry analysts at Foley & Lardner note the order moves psychedelics from "Schedule I to treatment priority". That tone shift alone may unlock new institutional investment.
Harvard's I. Glenn Cohen and Mason Marks call the order "as much a signal about the White House's change in attitude as anything else." They note presidents cannot legally compel DEA rescheduling.
Bioethicists have raised equity concerns. Priority Voucher access favors well-funded developers like Compass Pathways. Smaller nonprofits and indigenous-led organizations have fewer tools to navigate FDA review.
Safety researchers caution that fast-track review must still meet the FDA's evidence standard. A Risk Evaluation and Mitigation Strategy (REMS) program is likely required for any approved psychedelic. That program will shape how patients actually receive treatment.
President Trump signed the executive order 'Accelerating Medical Treatments for Serious Mental Illness' on April 18, 2026. The White House released the fact sheet and full text the same day. On April 24, 2026, the FDA awarded the first three National Priority Vouchers under the order.
No. The Trump psychedelics executive order does not legalize or reschedule any psychedelic. Psilocybin, MDMA, DMT, and ibogaine all remain Schedule I controlled substances under federal law. Possession is still a federal crime. The order only directs federal agencies to speed up review and access pathways for psychedelics in clinical development.
On April 24, 2026, the FDA awarded the first three National Priority Vouchers to: (1) Compass Pathways for COMP360 psilocybin for treatment-resistant depression; (2) Usona Institute for psilocybin for major depressive disorder; and (3) Transcend Therapeutics for methylone (TSND-201) for PTSD. MDMA was not in the first round.
The order allocates $50 million through ARPA-H (Advanced Research Projects Agency for Health) to match state government investments in psychedelic research programs for serious mental illness. The matching grant program rules are expected from ARPA-H in summer 2026.
No, but it gives ibogaine the most direct attention of any compound. The order directs the FDA and DEA to build a Right to Try pathway for investigational psychedelics including ibogaine. Harvard Law's Petrie-Flom Center notes ibogaine may not meet the statute's Phase I safety threshold, since most ibogaine research occurred overseas and cardiac safety data is limited.
No. Federal courts and legal scholars including Harvard's I. Glenn Cohen and Mason Marks have established that presidents cannot legally compel the DEA to reschedule a controlled substance. The order directs the Attorney General to initiate rescheduling reviews after Phase 3 trial completion, but the DEA already has a statutory 90-day duty after FDA approval. The provision is more signal than new legal power.
The National Priority Voucher Program targets a 1-2 month FDA review window, compared to the standard 6-10 months for a new drug application. This is faster than even Priority Review (typically 6 months) and Breakthrough Therapy designation alone.
No. The Oregon Measure 109 service centers and Colorado Prop 122 healing centers operate under state law and are not affected by the federal executive order. They will continue regardless of federal FDA approval timelines. The order's $50M ARPA-H matching grants could potentially benefit those states if they invest in research.
The Trump psychedelics executive order will keep generating FDA, DEA, and ARPA-H follow-on actions through 2026 and 2027. We track every new rule, voucher decision, and rescheduling step on our policy calendar.
→ See the psychedelic policy calendar · Read recent policy briefings
Get psychedelic policy research & policy updates
New trials, FDA decisions, and legal changes for psychedelic policy — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.